Novartis Spreads Cardiovascular Bets with Ionis Antisense Option Deal
Further expanding its cardiovascular pipeline, Novartis has signed an option deal with Ionis – and invested $100m into the smaller company – to license two investigational antisense drugs targeting cardiovascular indications in patients with elevated levels of lipoprotein.
You may also be interested in...
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.